RT Journal Article
SR Electronic
T1 Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.02.20030452
DO 10.1101/2020.03.02.20030452
A1 Zhang, Guqin
A1 Hu, Chang
A1 Luo, Linjie
A1 Fang, Fang
A1 Chen, Yongfeng
A1 Li, Jianguo
A1 Peng, Zhiyong
A1 Pan, Huaqin
YR 2020
UL http://medrxiv.org/content/early/2020/03/06/2020.03.02.20030452.abstract
AB Rationale In late December 2019, an outbreak of acute respiratory illness, now officially named as COVID-19, or coronavirus disease 2019, emerged in Wuhan, China, now spreading across the whole country and world. More data were needed to understand the clinical characteristics of the disease.Objectives To study the epidemiology, clinical features and outcomes of patients with COVID-19.Methods we performed a single center, retrospective case series study in 221 patients with laboratory confirmed SARS-CoV-2 pneumonia at a university hospital.Measurements and Main Results The median age was 55.0 years and 48.9% were male and only 8 (3.6%) patients had a history of exposure to the Huanan Seafood Market. Compared to the non-severe pneumonia patients, the median age of the severe patients was significantly older, and they were more likely to have chronic comorbidities. Most common symptoms in severe patients were high fever, anorexia and dyspnea. On admission, 33.0% patients showed leukopenia and 73.8% showed lymphopenia. In addition, the severe patients suffered a higher rate of co-infections with bacteria or fungus and they were more likely to developing complications. As of February 15, 2020, 19.0% patients had been discharged and 5.4% patients died. 80% of severe cases received ICU care, and 52.3% of them transferred to the general wards due to relieved symptoms, and the mortality rate of severe patients in ICU was 20.5%.Conclusions The COVID-19 epidemic spreads rapidly by human-to-human transmission. Patients with elder age, chronic comorbidities, blood leukocyte/lymphocyte count, procalcitonin level, co-infection and severe complications might increase the risk of poor clinical outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Natural Science Foundation of ChinaAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe declare all the data referred to our manuscript are available.